Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Subcutaneous Efgartigimod PH20 in Healthy Males
NCT04073589Phase 1Completed
- Sponsor
- argenx
- Start
- Jul 2019
- Primary completion
- Sep 2019
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (4 arms), sponsored by argenx. Primary endpoint: IgG levels of four different subcutaneous dose levels up to 11 weeks. Started Jul 2019; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04073589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073589.